PT1 – 25 mg

Brand:
Cayman
CAS:
331002-70-1
Storage:
-20
UN-No:
Non-Hazardous - /

PT1 is an activator of AMP-activated protein kinase (AMPK) that directly activates the inactive truncated forms of AMPK monomers α1335, α1394, and α2398 in a dose-dependent manner (EC50s = ~ 8, 8, and 12 µM, respectively).{33404} It stimulates the α1β1γ1 AMPK heterotrimer with an EC50 value of 0.3 μM.{33404} PT1 dose-dependently increases phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase, without increasing the cellular AMP:ATP ratio in L6 myotubes.{33404} In HepG2 liver cells, PT1 lowers lipid content through AMPK activation. PT1 induces autophagy in cardiomyocytes after oxygen glucose deprivation/reoxygenation, resulting in improved cell survival.{33403}  

 

Out of stock

SKU: 21335 - Category:

Description

An activator of AMPK that directly activates truncated monomers α1335, α1394, and α2398 (EC50s = ~ 8, 8, and 12 µM, respectively); stimulates the α1β1γ1 AMPK heterotrimer (EC50 = 0.3 μM); dose-dependently increases phosphorylation of AMPK without increasing the cellular AMP:ATP ratio in L6 myotubes


Formal name: 2-chloro-5-[[5-[[5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]-benzoic acid

Synonyms: 

Molecular weight: 497.9

CAS: 331002-70-1

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Activators|Kinases||Research Area|Cardiovascular System|Heart||Research Area|Cell Biology|Endomembrane System & Vesicular Trafficking|Autophagy||Research Area|Endocrinology & Metabolism|Metabolic Diseases